BRCA2 and neoplasm: In contrast to the Brca1-null TME, the treatment of Brca2-null tumour-bearing mice resulted in fewer significant changes in the immune cell populations found in the TME, as shown in the heatmap in Fig. 3B. The TME derived from Brca2-null group seem to exhibit a higher prevalence of negative z-scores, especially in response to olaparib alone (Fig. 3B).